Chardan lowered the firm’s price target on 4D Molecular (FDMT) to $28 from $30 and keeps a Buy rating on the shares. The firm is adjusting its model after the company’s Q4 earnings while noting that 4D Molecular is progressing with its phase 3 4FRONT-1 and 4FRONT-2 trials for 4D-150 in wet AMD, with topline data expected in the second half of 2027, while its interim phase 2b PRISM data has shown promising reductions in injection burden.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FDMT:
- 4D Molecular price target lowered to $35 from $39 at RBC Capital
- Promising Developments in 4D Molecular Therapeutics’ Gene Therapy Program Justify Buy Rating
- 4D Molecular Therapeutics Reports Strong Clinical Progress and Financial Position
- Optimistic Buy Rating for 4D-150 Driven by PRISM Study’s Promising Results in Treating Wet Age-Related Macular Degeneration
- 4D Molecular price target lowered to $30 from $39 at Chardan